Home » News » 01/06 » Merck KGaA drops Pegasus project

Merck KGaA drops Pegasus project

Date published: 01/01/2006

Merck KGaA has announced it has dropped its plan to make acquisitions in its chemical division. The plan, known as Pegasus, was dropped because a major acquisition was thought to be too expensive.

However, Merck KgaA has refused to rule out any further takeovers in other areas, including pharmaceuticals as well as chemicals.

Financial Times Deutschland reported that through an acquisition the company had intended to double revenue from chemicals to 3.5 billion euros a year from 2008 and boost earnings from the business to 800 million euros a year.

Merck spokeswoman Phyllis Carter told Bloomberg: "We looked for a long time. "Sometime in 2005 it became apparent we weren't going to find our Pegasus."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.